[191 Pages Report] The Cancer Biopsy Market size was estimated at USD 29.84 billion in 2023 and expected to reach USD 33.48 billion in 2024, at a CAGR 12.28% to reach USD 67.14 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Biopsy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Biopsy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
    • Kits & Consumables
    • Services
  • Type
    • Liquid Biopsies
    • Tissue Biopsies
      • Needle Biopsies
        • Core Needle Biopsy
        • Fine Needle Aspiration
      • Surgical Biopsies
  • Indication
    • Blood Cancers
    • Breast Cancer
    • Cervical Cancers
    • Colorectal Cancer
    • Kidney Cancers
    • Liver Cancers
    • Lung Cancers
    • Ovarian Cancers
    • Pancreatic Cancers
    • Prostate Cancers
    • Skin Cancers

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Cancer Biopsy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Biopsy Market?
  3. What are the technology trends and regulatory frameworks in the Cancer Biopsy Market?
  4. What is the market share of the leading vendors in the Cancer Biopsy Market?
  5. Which modes and strategic moves are suitable for entering the Cancer Biopsy Market?